Engineering of injectable hydrogels associate with Adipose-Derived stem cells delivery for anti-cardiac hypertrophy agents. (1st January 2021)

• Record Type: Journal Article
• Authors: Long, Guangyu; Wang, Quanhe; Li, Shaolin; Tao, Junzhong; Li, Boyan; Zhang, Xiangxiang; Zhao, Xi
• Is Part Of: Drug delivery. Volume 28:Number 1(2021)
• Page Start: 1334
• Page End: 1341
• Publication Date: 2021-01-01
• Subjects: Adipose-derived stem cells -- Injectable hydrogels -- alginate sericin laminin -- anti-cardiac -- hypertrophy; Drug delivery systems -- Periodicals; Drug targeting -- Periodicals; 615.05
• DOI: 10.1080/10717544.2021.1943060
• Languages: English
• ISSNs: 1071-7544

Abstract

Abstract: Adipose-derived stem cells (ADSCs) treatment offers support to new methods of transporting baseline cell protein endothelial cells in alginate (A)/silk sericin (SS) lamellar-coated antioxidant system (ASS@L) to promote acute myocardial infarction. In the synthesized frames of ASS, the ratio of fixity modules, pores, the absorption and inflammation was detected at ka (65ka), 151 ± 40.12 μm, 92.8%, 43.2 ± 2.58 and 30.10 ± 2.1. In this context, ADSC-ASS@L was developed and the corresponding material was stable and physically chemical for the development of cardiac regenerative applications. ADSC-ASS@L injectable hydrogels in vitro examination demonstrated higher cell survival rates and pro-angiogenic and pro-Inflammatory expression factors, demonstrating the favorable effect of fractional ejections, fibre-areas, and low infracture vessel densities. In successful cardiac damage therapy in acute myocardial infarction the innovative ADSC injection hydrogel approach may be helpful. The approach could also be effective during coronary artery hypertrophy for successful heart damage treatment.